{"organizations": [], "uuid": "7257dc3fcf9b28346ac55cbcf290ac0a5a589bcf", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180306.html", "section_title": "Archive News &amp; Video for Tuesday, 06 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/bristol-myers-fda/fda-approves-new-dosing-for-bristol-myers-squibbs-opdivo-idUSL4N1QO43T", "country": "US", "domain_rank": 408, "title": "FDA approves new dosing for Bristol-Myers Squibb's Opdivo", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.986, "site_type": "news", "published": "2018-03-06T20:18:00.000+02:00", "replies_count": 0, "uuid": "7257dc3fcf9b28346ac55cbcf290ac0a5a589bcf"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/bristol-myers-fda/fda-approves-new-dosing-for-bristol-myers-squibbs-opdivo-idUSL4N1QO43T", "ord_in_thread": 0, "title": "FDA approves new dosing for Bristol-Myers Squibb's Opdivo", "locations": [], "entities": {"persons": [{"name": "manas mishra", "sentiment": "none"}, {"name": "maju samuel", "sentiment": "none"}], "locations": [{"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "u.s. food and drug administration", "sentiment": "negative"}, {"name": "bristol-myers squibb", "sentiment": "negative"}, {"name": "reuters) - bristol-myers squibb co", "sentiment": "neutral"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 6 (Reuters) - Bristol-Myers Squibb Co said on Tuesday the U.S. Food and Drug Administration had approved a new dosing schedule for its drug, Opdivo, across a number of cancers the drug is already approved to treat.\nThe approval was related to a marketing application for an infused 480 mg dose every four weeks.\nOpdivo is already approved to treat a number of cancers such as melanoma. (Reporting by Manas Mishra in Bengaluru; Editing by Maju Samuel)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-06T20:18:00.000+02:00", "crawled": "2018-03-07T19:53:48.007+02:00", "highlightTitle": ""}